Iambic Therapeutics doubles series A raise in push toward clinic

A privately-held drug discovery company based in San Diego, USA, has raised $100 million in a series B financing co-led by Ascenta Capital and Abingworth.

Iambic Therapeutics, which was formerly known as Entos, is leveraging a generative AI discovery platform which uses physics-informed machine learning and experimental automation.

Iambic has discovered two candidates to advance into the clinic: IAM-H1, a selective and brain-penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor.